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Abstract
Introduction Exercise is widely accepted to improve health, reducing the risk of premature mortality, cardiovascular dis-
ease (CVD) and cancer. However, several epidemiological studies suggest that the exercise-longevity relationship may be 
‘J’ shaped; with elite athlete’s likely training above these intensity and volume thresholds. Therefore, the aim of this meta-
analysis was to examine this relationship in former elite athletes.
Methods 38,047 English language articles were retrieved from Web of Science, PubMed and SportDiscus databases pub-
lished after 1970, of which 44 and 24 were included in the systematic review and meta-analysis, respectively. Athletes were 
split into three groups depending on primary sport: Endurance (END), Mixed/Team, or power (POW). Standard mortal-
ity ratio’s (SMR) and standard proportionate mortality ratio (SPMR) were obtained, or calculated, and combined for the 
meta-analysis.
Results Athletes lived significantly longer than the general population (male SMR 0.69 [95% CI 0.61–0.78]; female SMR 
0.51 [95% CI 0.40–0.65]; both p < 0.01). There was no survival benefit for male POW athletes compared to the general popu-
lation (SMR 1.04 [95% CI 0.91–1.12]). Although male athlete’s CVD (SMR 0.73 [95% CI 0.62–0.85]) and cancer mortality 
(SMR 0.75 [95% CI 0.63–0.89]), were significantly reduced compared to the general population, there was no risk-reduction 
for POW athletes CVD mortality (SMR 1.10 [0.86–1.40]) or END athletes cancer mortality (SMR 0.73 [0.50–1.07]). There 
was insufficient data to calculate female sport-specific SMR’s.
Discussion Overall, athletes live longer and have a reduced incidence of both CVD and cancer mortality compared to the 
general population, refuting the ‘J’ shape hypothesis. However, different health risks may be apparent according to sports 
classification, and between sexes, warranting further investigation.
Trial registration PROSPERO (registration number: CRD42019130688).
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1 Introduction
The benefits associated with regular exercise for physical and 
mental health in the general population are well-evidenced, 
with inactivity strongly correlated with an increased risk of 
premature mortality [1–4]. Indeed, mortality associated with 
cardiovascular disease (CVD) and cancer, the most prevalent 
causes of mortality worldwide [5], is exacerbated by physi-
cal inactivity [6, 7] and decreased by regular exercise [6, 8]. 
Specifically, it is suggested that for every one unit increase 
in maximal metabolic equivalent of task (MET) capacity, 
the likelihood of CVD mortality is reduced by 15% [6]. 
Similarly, cancer incidence and mortality rates were 27 and 
37% lower in the fittest and least fit group, respectively, in a 
16-year longitudinal study of Finnish men [9]. Furthermore, 
this relationship persisted even after accounting for smok-
ing habits, alcohol intake, waist-to-hip ratio, socioeconomic 
status and nutritional intake, highlighting the importance of 
exercise in the prevention of cancer [9].
Despite the benefits associated with regular exercise, there 
is a body of evidence that suggests the exercise-longevity 
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Key Points 
Elite athletes live longer than the general population.
Sport-specific differences in mortality, and disease, risk 
may be evident.
More research is needed to examine the impact of an 
elite sporting career in female athletes with a minimum 
follow-up period of 30 years.
athletes, according to sport type, in comparison to their non-
elite counterparts.
2  Methods
2.1  Data Sources, Literature Search and Inclusion 
Criteria
This systematic review was registered on PROSPERO (reg-
istration number: CRD42019130688) and was conducted in 
accordance with the PRISMA guidelines [24, 25]. The key-
words were split into three levels to search scientific data-
bases and were compromised of the following (1) mortality 
or death or longevity; (2) elite or athletes or Olympic; and 
(3) excessive or training or chronic exercise. All keywords 
were used in combination and different iterations to capture 
all results, with the full search terms available in the Sup-
plementary Material.
The inclusion criteria for studies in the meta-analysis 
was: (1) written in the English language; (2) experimental 
participants were male or female former athletes of at least 
national standard, with some information on their sporting 
history provided; (3) the study included a general popula-
tion reference group; (4) data were reported on mortality, 
CVD and/or cancer-specific mortality in male or female 
athletes; (5) data were reported as a standardised mortality 
ratio (SMR), or standardised proportional mortality ratio 
(SPMR), with 95% confidence limits, or provided sufficient 
data (observed/expected mortality) to allow either SMR or 
SPMR to be calculated; and (6) the studies were of a retro-
spective, or prospective, methodological design. Any non-
peer-reviewed grey literature, including conference papers 
and theses, were excluded. Moreover, any studies that had 
a follow-up of ≤ 5 years were excluded, along with studies 
which reported the primary outcome of mortality but did 
not use SMR, or the data was not provided to allow this to 
be calculated. In the case of any disagreements regarding 
the inclusion of a study that were not able to be resolved 
(between AR and MM), KM was consulted to reach a con-
sensus, which occurred on five occasions.
Studies were searched for, and identified, through scien-
tific databases and by scanning the reference list of iden-
tified studies. The search was performed in Web of Sci-
ence (1970–2019), PubMed (1970–2019) and SportDiscus 
(1970–2019). All potentially relevant studies, including ref-
erence lists and abstracts, were compiled in Rayyan QCRI 
software [26]. Two authors (AR and MAM) then screened 
all identified titles and abstracts to identify studies for full-
text review. From an initial search of 38,047 results, 37,878 
were excluded. Consequently, 169 were taken forward for 
relationship may be ‘J’ shaped, with exercise beyond cer-
tain volume and intensity thresholds detrimental to health 
[10–15]. Specifically, Mohlenkamp et al. [15] reported that, 
over a two-year observational period, recreational German 
marathon runners had a similar incidence of a cardiovascular 
(CV) event compared to a population with established coro-
nary heart disease (CHD). Furthermore, the Copenhagen 
Heart Study reported light and moderate joggers to demon-
strate lower mortality hazard ratios (0.22 and 0.66, respec-
tively) compared to strenuous joggers (HR 1.97) [14]. Simi-
larly, those who exercised every day in the Million Women 
study were at an increased risk of a CV event compared to 
women who had at least one rest day during the week [13].
Elite athletes typically engage in training at levels far 
exceeding those reported in epidemiological studies, rais-
ing questions as to whether elite athletes are potentially at 
an elevated risk of premature mortality, CVD and/or can-
cer [10, 12, 13]. Such a concept has received considerable 
research attention. Indeed, two recent systematic reviews 
and a meta-analysis investigated the relationship between 
long-term intensive training, health, and mortality in elite 
athletes and the general population [16–18]. Taken together, 
these reviews suggest that elite athletes live longer than the 
general population and have a lower mortality rate from 
both CVD and cancer [16–18]. However, these reviews did 
not stratify by sport type (i.e. aerobic, power, team sports). 
Consequently, the importance of training types and sporting 
demands, therefore, largely remains to be elucidated. For 
example, in comparison to endurance athletes, power (POW) 
sport athletes have an increased body mass index (BMI) [19, 
20], which is an independent risk factor for future CVD [21]. 
Furthermore, endurance (END) training has been shown to 
lower several key inflammatory markers [22], which, whilst 
this remains contentious, could reduce the risk of long-term 
CVD risk [15, 23].
Therefore, the aim of this systematic review and meta-
analysis was to examine the relationship between chronic 
intensive exercise training and mortality in former elite 
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full-text review of which 43 were finally included within the 
systematic review (Table 1); 24 of which were also appropri-
ate for the meta-analysis (Fig. 1).
2.2  Data Extraction
A data table was created extracting the following informa-
tion: authors and year of publication, number of participants 
followed, the primary sport of those athletes (if available), 
how long the athletes were followed for, all-cause mortality 
SMR, CVD-specific SMR and cancer-specific SMR. When 
SMR was not directly reported, it was calculated from the 
reported observed and expected deaths as SMR = observed 
(O) death/expected (E) death [18]. If the expected number 
of deaths was not reported from population data, the num-
ber in the referent group was used as the expected value 
and the SPMR defined as (athlete observed death/number in 
athlete population)/(control group death/number in the con-
trol group). To calculate 95% confidence intervals (CI) for 
both methods, the formula: SMR or SPMR ± (1.96 * stand-
ard error of estimate; SEE) defined as √ (O)/E [27] was 
used. These two metrics are, therefore, uniform and can be 
combined to create a pooled SMR. The Newcastle–Ottawa 
Quality Assessment tool [28] was used to assess the quality 
of each study included within the meta-analysis.
Following the overall risk calculations, specific SMR’s 
were calculated, where possible, according to sport. Spe-
cifically, in line with other research, END activities were 
defined as any sport requiring more than 10 min of continu-
ous effort [29]. The END sports in the meta-analysis meet-
ing this criterion were: middle- and long-distance runners, 
rowers, cross-country skiers, ice skaters and tour de France 
cyclists. A ‘team sport’ was defined as any sport in which the 
performance is predominantly made up of repeated intermit-
tent efforts [29]. Team sports identified in this meta-analysis 
were American footballers, baseball players, footballers, ice 
hockey players and basketball players. Finally, POW sports 
were defined as any predominantly anaerobic sport [30]. The 
sports in the POW category for this meta-analysis included: 
boxers, wrestlers, weightlifters, and throwing events in track 
and field.
2.3  Statistics
All meta-analyses statistics were performed using meta, 
metagen and metaforest packages in R Studio (R Studio 
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Fig. 1  Schematic flow diagram of the systematic review and meta-analysis process
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v1.2.2019, R Studio, Boston, MA) to calculate the pooled 
SMR and create the subsequent forest plots. Initially, all 
SMR and SPMR, values, and their 95% CI’s were logged 
to determine effect sizes on a natural scale and then the 
SEE was calculated for each study. The resulting data were 
then run through metagen, where the pooled SMR was 
back-transformed to the original SMR scale. The pooled 
SMR indicates the risk in athletes compared to the general 
population, with a value of < 1 indicating a lowered risk, 
> 1 indicating a greater risk and 1 indicating the same risk. 
Meta-regressions were also run to establish the relationships 
between outcome variables and possible confounding fac-
tors using the metareg function in R. The pooled SMR was 
calculated using a random-effects model with heterogeneity 
assessed using the I2 and Q statistic. Risk of publication 
bias assessed using a combination of the Egger’s Statistic 
and funnel plots.
3  Results
The total number of athletes included within the 24 stud-
ies was 165,033, with 139,322 males (84.4%) and 25,711 
females (15.6%). There was insufficient data to split the 
females by sport type, so this was only done for male ath-
letes. Of the male sample, 78,096 (47.3%) were END ath-
letes, 78,689 (47.7%) were team sport athletes, 3,202 (1.9%) 
were POW sport athletes, and 5046 (3.1%) of the athletes 
were Olympians/World Champions where their primary 
sports could not be established. All included studies were 
of retrospective methodological design.
The Newcastle–Ottawa scale assesses the methodologi-
cal quality, and generalisability of an individual study, with 
higher scores indicating high methodological quality. Of 
a possible maximum score of 9 on the Newcastle–Ottawa 
quality score, five, six, nine and four papers scored nine 
[30–34], eight [35–40], seven [41–49] and six [50–53], 
respectively. Funnel plots were used to assess publication 
bias (Supplementary Figures 2–4), with all-cause, CVD, and 
cancer mortality demonstrating publication bias, indicated 
by the wide range of log SMRs reported in the included 
studies.
Overall, all-cause mortality in male and female athletes 
was reported in 23 out of 24 studies (164,833 athletes), cre-
ating a pooled SMR of 0.67 (95% CI 0.59–0.75; p < 0.01), 
with some evidence of publication bias [p < 0.05 (Supple-
mentary Figure 2)] and significant heterogeneity (I2 = 96.9%; 
Q = 850.7; p < 0.01). Sub-group analyses revealed male all-
cause mortality was reported in 23 studies [30–48, 50–53] 
(139,122 athletes; 99.7% of all male athletes), creating a 
pooled SMR of 0.69 (95% CI 0.61–0.78; p < 0.01), with 
no evidence of publication bias (p = 0.07) and significant 
heterogeneity (I2 = 97.0%; Q = 730.3; p < 0.01) (Fig. 2). 
Female all-cause mortality was reported in four studies 
[36, 43, 44, 47] (25,711 female athletes; 100%) leading to a 
pooled SMR of 0.51 (95% CI 0.40–0.65, p < 0.01), with no 
evidence of bias (p = 0.41) and no significant heterogeneity 
(I2 = 45.1%, Q = 5.5, p > 0.05) (Fig. 3). There was insuffi-
cient data to calculate a meta-SMR for either CVD or cancer 
mortality in females, therefore, this was only performed in 
male athletes.  
Overall, male CVD mortality was reported in 15 stud-
ies [30, 32–34, 36–39, 41, 42, 45–47, 49, 50, 53] (118,288 
athletes, 84.8%), demonstrating a pooled SMR of 0.73 (95% 
CI 0.62–0.85; p < 0.01), with no publication bias (p = 0.26) 
and significant heterogeneity (I2 = 81.8%, Q = 82.6, p < 0.01) 
(Fig. 4). Overall cancer mortality was reported in 17 studies 
[30, 31, 33–39, 41, 42, 45–47, 49, 51, 53], with a pooled-
SMR of 0.75 (95% CI 0.63–0.89, p < 0.05), no evidence of 
publication bias (p = 0.28) and significant heterogeneity 
(I2 = 88.1%, Q = 143.1, p < 0.01) (Fig. 5).
Endurance and team sport athlete’s all-cause (END: 
I2 = 98.7%, p < 0.01; Team: I2 = 97.0%, p < 0.01) and CVD 
mortality (END: I2 = 96.3%, p < 0.01; Team: I2 = 78.0%, 
p < 0.01) was significantly lower than the general population, 
however, POW athletes’ all-cause (I2 = 77.8%, p > 0.81) and 
CVD (I2 = 84.9%, p > 0.46) mortality was not significantly 
different to the general population. For cancer-specific mor-
tality, both team (I2 = 86.2%, p < 0.01) and POW (I2 = 53.3%, 
p < 0.01) athletes pooled-SMR’s were significantly lower 
than the general population, but endurance athlete cancer 
mortality was not (I2 = 96.1%, p > 0.11). All of the sub-
analyses were heterogeneous (p > 0.05), with the exception 
of cancer mortality for power athletes (p < 0.05), with no 
evidence of bias except for team sport all-cause mortality 
[Eggers test p < 0.05 (Table 2)].
3.1  Meta‑Regression and Sensitivity Analyses
Sensitivity analyses revealed that when (1) the four-lowest 
quality studies were removed; (2) only studies incorporat-
ing athletes actively competing after 1945; or (3) only stud-
ies published after 2010 were included, the pooled SMR 
remained similar to the overall SMR (0.64–0.68). Indeed, 
meta-regressions demonstrated no significant interaction 
with SMR for any of the three data constraints. However, 
when studies with ≤ 30 years follow-up were excluded, the 
pooled SMR increased to 0.74 (95% CI 0.65–0.84). Moreo-
ver, a significant positive association was observed between 
follow-up length and all-cause (β = 0.01, Z = 2.94, p < 0.01) 
and cancer mortality (β = 0.01, Z = 1.93, p > 0.05). How-
ever, no significant association was reported between fol-
low-up length and CVD mortality SMR (β < 0.01, Z = 0.90, 
p = 0.36).
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4  Discussion
This was the first systematic review and meta-analysis to 
examine sport-specific all-cause mortality in former elite 
athletes and to consider CVD- and cancer-specific mortality, 
the two most prevalent diseases worldwide. The key findings 
from this review are: (1) male and female elite athletes live 
longer than the general population; (2) male athletes have 
a lower incidence of CVD and cancer mortality than the 
general population; (3) power sport athletes all-cause and 
CVD mortality were not significantly different to the gen-
eral population; (4) endurance athletes cancer mortality was 
not significantly different to the general population and (5) 
increased follow-up length increased the SMR for all-cause 
and cancer mortality, but not CVD. Furthermore, there is 
currently insufficient data to allow sport-level comparisons 
for female athletes.
4.1  All‑Cause Mortality
Over recent years, an argument has been made that chronic, 
intensive exercise may be harmful to health [10–12] and lead 
to a greater chance of premature mortality, or an increased 
incidence cardiovascular events [14, 15, 54]. However, the 
current evidence refutes these arguments; male and female 
athletes had a 31 and 49% lower risk of all-cause mortal-
ity than the general population, respectively. This seems 
to indicate that the female survival advantage (females are 
expected to live 6–8 years longer than males at birth [55]) 
persists, and is even extended, after a career in elite sport. 
However, female mortality was only explored in 25,711 ath-
letes, 24,403 (94.9%) of which were identified from a sin-
gle study [47], hence there was no significant heterogeneity 
within the pooled-SMR generated. Therefore, more research 
in female athletes is needed to confirm the survival benefit 
in highly active female athletes. Moreover, more research 
Fig. 2  Overall male mortality 
forest plot
Fig. 3  Overall female mortality 
forest plot
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Table 1  Key information about the studies included within the meta-analysis





CVD mortality SMR 
(95% CI)
Cancer mortality SMR 
(95% CI)
Sarna et al. [30] 2613 former Finnish 
athletes
1712 military control 
participants
44.5 0.92 (0.84–1.01) 0.95 (0.81–1.09) 0.96 (0.75–1.11)
Kettunen et al. [35] 2263 former Finnish 
athletes
1657 military control 
participants
50 0.98 (0.91–1.05) # 0.89 (0.76–1.03)
Lincoln et al. [41] 9778 former NFL 
players
US reference values
18.5 0.46 (0.40–0.52)** 0.68 (0.50–0.90)** 0.41 (0.26–0.62)**
Antero-Jacquemin et al. 
[36]





20.3–43.7 M 0.51 (0.45–0.59)**
F 0.49 (0.26–0.85)**
M 0.55 (0.41–0.73)**
Insufficient data to 
compute F SMR
M 0.55 (0.43–0.69)**
Insufficient data to com-
pute F SMR




32.5 0.59 (0.51–0.68)** 0.67 (0.50–0.88)** 0.56 (0.42–0.72)**
Kontro et al. [31] 900 former Finnish 
athletes
900 brothers of the 
Finnish athletes
77.5 1.00 (0.93–1.08) # 1.47 (1.22–1.73)**
Grimsmo et al. [50] 122 endurance skiers
Norwegian population 
reference values
30 0.78 (0.50–1.05) Not reported Not reported
Antero-Jacquemin et al. 
[37]




50 0.58 (0.43–0.78)** 0.41 (0.16–0.84)** 0.59 (0.29–1.07)
Menotti et al. [43] 983 (283 female) 
former track and field 
athletes




Not reported Not reported
Gajewski and Poznan-
ska [44]
2113 (424 Female) for-








Not reported Not reported




47.5 0.74 (0.69–0.79)** 0.72 (0.64–0.82)** ##
Lehman et al. [38] 3439 former NFL 
players
US population reference 
values
33.5 0.53 (0.48–0.59)** 0.68 (0.56–0.81)** 0.58 (0.46–0.72)**
Waterbor et al. [51] 958 MLB players
US population reference 
values
59 0.94 (0.88–1.00) # 1.05 (0.89–1.22)
Taioli [45] 5389 Italian footballers
Italian population refer-
ence values
28 0.68 (0.52–0.86) 0.41 (0.20–0.73) 0.31 (0.15–0.55)
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including a follow-up period of ≥ 30 years are needed given 
the positive association between reduced survival estimates 
and follow-up time.
Given that the standardised mortality ratio was the most 
common method of reporting the risk of mortality in elite ath-
letes, this method was chosen for the meta-analysis. However, 
life expectancy and age at death in male athletes has also been 
explored. Specifically, Clarke et al. [56] reported an average 
2.8 year survival advantage in a cohort of 15,174 Olympic ath-
letes from nine countries, with a cohort study of 2814 French 
Olympians gaining an average of 6.5 years [29]. These results 
are, therefore, largely in accord with those of the current meta-
analysis, as the lowered SMR risk indicates a longer survival in 
former elite athletes compared to the general population.
Despite the apparent survival benefit of elite athletes, 
one common and important criticism of the literature is 
CI confidence interval, SMR standardised mortality ratio, NFL national football league, MLB major league baseball, M male, F female
SMR’s in bold indicate a significant difference between the athletes and the control population (p < 0.05). #Kettunen et al. [35], Kontro et al. 
[31], Mackay et al. [40] all reported specific SMR values on Ischemic Heart Disease (IHD) respectively, and Waterbor et al. [51] reported SMR 
values for Arteriosclerotic Heart Disease therefore they were removed from CVD analyses as overall CVD mortality was assessed. ##Mackay 
et al. [40] and Kujala et al. [32] report SMR’s for lung cancer specifically and so they were removed from the overall analysis as overall cancer 
mortality was assessed
Table 1  (continued)





CVD mortality SMR 
(95% CI)
Cancer mortality SMR 
(95% CI)




66 0.96 (0.79–1.12) 0.95 (0.67–1.34) 0.94 (0.61–1.44)




32 0.76 (0.68–0.85) Not reported Not reported



















35 0.73 (0.56–0.94) 0.61 (0.38–0.93) 0.70 (0.40–1.12)
Baron et al. [33] 3439 NFL players
US population reference 
values
34 0.53 (0.46–0.72) 0.68 (0.56–0.81) 0.58 (0.46–0.73)




18 0.93 (0.91–0.95) # ##
Nguyen et al. [34] 16,637 former MLB 
players
US population reference 
values
36 0.76 (0.73–0.78) 0.81 (0.77–0.85) 0.80 (0.75–0.86)
Kalist and Peng [48] 2641 former MLB 
players
US population reference 
values
20 0.31 (0.23–0.39) Not reported Not reported




18 1.00 (0.90–1.10) 0.83 (0.69–1.00) 1.11 (0.97–1.28)
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the applicability of comparing former elite athletes to the 
general population. Elite athletes may be characterised 
by healthier lifestyles post-retirement than the general 
population and engage in more leisure-time physical activ-
ity (LTPA), both of which predict all-cause mortality 
[31, 44, 57, 58]. It is, therefore, not currently possible to 
Fig. 4  Overall male cardiovas-
cular mortality forest plot
* Gadja et al. [49] presented two separate standard mortality risk (SMR) scores for ages 
under, and over, 65 which was impossible to separate. The star highlights the SMR for over 
65’s
Fig. 5  Overall male cancer 
mortality forest plot
* Gadja et al. [49] presented two separate standard mortality risk (SMR) scores for ages 
under, and over, 65 which was impossible to separate. The star highlights the SMR for 
over 65’s
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distinguish the influence of intensive training per se from 
overall lifestyle factors. Indeed, it may be worth noting that 
when Sarna et al. [30] and Kettunen et al. [35] used a control 
group formed of military fit personnel, the SPMR was not 
significantly different relative to elite athletes (0.92 and 0.98, 
respectively). Additionally, some studies have only reported 
survival benefits up to a specific age, rather than across the 
whole lifespan [40, 46, 49]. Specifically, Schnohr [46] found 
that athletes up to 50 years had a SMR of 0.61, with ath-
letes aged over 50 and 65 years having SMR’s of 1.08 and 
1.02, respectively. Similarly, former Scottish footballers only 
had a survival benefit up to the age of 60 years [40], with 
Polish footballers having a benefit until 75 years [49], after 
which the mortality was the same or greater than the general 
population. Conversely, Antero-Jacquemin [29] reported an 
increased longevity in French Olympians after 50 years of 
age, thus, it is unknown why this apparent loss of survival 
advantage occurs, in some, but not all, athletes. Further work 
is needed to elucidate the potential mechanisms.
4.2  Sport‑Specific Mortality
Male END athletes had the most favourable all-cause mor-
tality rate and lived significantly longer than the general 
population (SMR 0.65). Indeed, Clarke et al. [56] reported 
a 13% greater survival benefit for medallists in endurance 
sports, with similar benefits reported in marathon runners 
(+ 4.3 years [59]), tour de France cyclists (+ 8 years [60]) 
and Olympians involved in endurance sports (+ 6.3 years 
[29]). Endurance athletes have consistently been shown to 
have favourable mortality compared to the general popu-
lation, attributed to an increased cardiorespiratory fitness 
(CRF) and subsequent maintenance of CRF throughout 
the lifespan. Specifically, every 1 MET increase in maxi-
mal capacity reduces the likelihood of all-cause mortality 
by 15% [6]. Furthermore, the difference is unlikely to be 
explained by genetic factors as it has recently been shown 
that elite athletes who undertake strenuous aerobic exercise 
exhibit similar disease-trait-related genotypes to the general 
population [61]. Thus, endurance athletes are still predis-
posed to similar levels of disease to the general population.
Male team sport athletes, the biggest sub-group within 
the meta-analysis including 78,504 (56.4%) of all male ath-
letes, also demonstrated a favourable all-cause mortality 
(SMR 0.68). However, it must be noted that significant bias 
was evident (Eggers statistic p = 0.01) and so these results 
should be interpreted with caution. This may be explained, at 
least in part, by two studies in the team sport meta-analysis 
including athletes competing before 1915 [46, 51]. Specifi-
cally, sporting practices, training demands, athlete welfare 
and advances in health care make it difficult to directly com-
pare across such a large time-span and gain reliable results. 
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sports report a survival benefit in former baseballers (+ 4 
to 5 years [62–64]), American football players (+ 6.1 years 
[65]) and basketballers (+ 4.3 to 5.5 years [66]), but the same 
was not observed in footballers (− 1.9 years [67]). It should 
be acknowledged, however, that three of these studies, con-
ducted by Abel and Kruger [62, 63, 65], also involved ath-
letes who made their professional debuts before 1940, so 
the applicability of their findings to a modern population is 
questionable. Furthermore, Kuss et al. [67] failed to account 
for world war deaths, confounding conclusions and poten-
tially explaining the reduced survival incidence reported. 
Nevertheless, despite these methodological limitations, they 
advance our understanding, although the generalisability of 
their results remains questionable and conclusions must be 
drawn with caution.
Power sport athlete’s all-cause mortality was not signifi-
cantly different from that of the general population (pooled-
SMR 1.04), however, this analysis was only conducted in 
two studies with participants totalling 2826, or 2.0%, of 
the overall population. Similar patterns are evident in other 
studies, with male discus throwers (− 0.6 years) and 100 m 
runners (− 0.9 years) experiencing marginal premature mor-
tality [59]. In contrast, Clarke et al. [68] reported a modest 
survival benefit in power athletes, albeit of only 5%. For-
mer Olympic male wrestlers have also been reported to live 
13.0 ± 18.4 years longer, although this must be interpreted 
with caution given that the standard deviation spans 0, indi-
cating some have a premature mortality, and the relatively 
small sample size included within this study (n = 341) [69]. 
However, contradicting the negative associations of all-cause 
mortality and power sports, Antero-Jacquemin et al. [29] 
reported power athletes gained an average of 7.2 years, sug-
gesting a significantly longer life-span. Given the disparity 
of results across the literature and the small statistical power 
within this meta-analysis, more research is needed to fully 
elucidate the long-term effects of competing in power sports.
4.3  Cardiovascular Disease Mortality
Overall, the pooled-SMR risk of CVD mortality (0.73) was 
significantly lower than the general population. This is not 
surprising given the long-established relationship between 
CRF and CVD mortality [70]. Specifically, men in the high-
est quintile of fitness, compared to those in the lowest, had 
a relative risk of 0.22 (0.12–0.39) for CVD mortality [71], 
and as little as 1 ml⋅kg−1⋅min−1 increase in CRF decreased 
the risk of CVD mortality by 9% [72]. Cardiorespiratory 
fitness is critical for most END and team sports athlete’s per-
formance and, consequently, these athletes occupy the top 
percentile for CRF values and present the lowest risk (SMR 
0.63 and 0.76, respectively). Thus, the superior CRF and 
consequent lower CVD mortality risk in team and END ath-
letes is one of the main reasons suggested for the observed 
increased longevity in END and team athletes [16, 29], and 
the lack of protective effect in power athletes (SMR 1.10).
Four studies [31, 35, 40, 51] were not included within the 
meta-analysis for CVD mortality as they reported a SMR 
value for the specific CVD of ischemic heart disease (IHD) 
[31, 35, 40] or arteriosclerotic heart disease (AHD) [51]. 
Including specific CVD SMR’s, as opposed to overall CVD 
risk, could have induced bias and so the decision was made 
to remove them. However, the SMR for IHD was not sig-
nificantly different in former Finnish athletes (SMR 0.95 
(0.81–1.09) [31]; SMR 1.00 (0.86–1.14) [35]) or former 
Scottish footballers (SMR 0.91 (0.87–0.96) [40]), in rela-
tion to the general population. Similarly, AHD mortality risk 
was not significantly different in 958 former baseball players 
(SMR 1.10 (0.99–1.22)) [51]. Furthermore, a recent study in 
French Olympians reported END athletes are at an increased 
risk of mortality due to CVD, cumulating in a loss of 1.6 
(4.8, 1.2) years [29]. Taken together, these results indicate 
that END and team athletes may be protected against some, 
but not all, CVDs. This may, at least in part, explain the 
overall protective effect of exercise but the minimal impact 
on IHD and AHD. However, more research is needed to 
confirm this hypothesis and to establish whether intensive 
training lowers the specific risk profile and aetiologies of 
individual CV diseases.
Power athletes pooled-SMR was not significantly differ-
ent to that of the general population for CVD (SMR 1.10), 
however, caution is warranted when interpreting this finding 
as only 1885 male athletes (1.2%) from two studies [30, 32] 
were included. Nevertheless, American football linemen, 
who share a lot of characteristics with power sport athletes, 
had a two to threefold increase in CVD mortality compared 
to counterparts in other positions [33, 41]. One possible 
explanation is the increased likelihood of hypertension in 
power athletes [32, 73, 74], a long-established independent 
CVD risk factor. Additionally, power sport athletes charac-
teristically have a higher BMI and a relationship between 
playing/competing time BMI and CVD mortality has been 
observed [33]. Specifically, American football players who 
had a playing time BMI of ≥ 30 kg⋅m2 had twice the risk of 
CVD mortality (SMRs 2.02–2.07), compared to those with 
a BMI ≤ 29.9 kg⋅m2 [33]. This risk could be further exac-
erbated as over a 30-year period power athletes reportedly 
gained an average of 12.8 kg [75]. So, a question remains as 
to whether playing-time BMI is the primary risk factor of 
CVD or subsequent weight-gain post-retirement is a greater 
indicator of CVD mortality in power athletes.
4.4  Cancer Mortality
Cancer mortality (SMR 0.75) was significantly lower in ath-
letes than the general population. Likewise, elite French ath-
letes had a significantly lower incidence of cancer mortality, 
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gaining an average of 2.3 (1.9–2.6) years [29]. One pos-
sible explanation is that former athletes smoke less, drink 
less, and engage in more LTPA than the general popula-
tion [31, 57, 58, 76], all of which significantly contribute 
to cancer risk and mortality. Indeed, Sourmunen et al. [76] 
reported that when LTPA, smoking status, years of smoking 
and alcohol consumption were accounted for, there was a 
minimal protective effect on cancer incidence (standardised 
incidence ratio 0.89 (0.81–0.97)). Moreover, Pukkala et al. 
[77] reported that elite athletes had a slightly elevated inci-
dence of non-smoking related cancers (SIR 1.10), with other 
studies reporting lung cancer mortality was significantly 
reduced in athletes [32, 40]. This confirms the importance of 
accounting for lifestyle-related habits when assessing cancer 
incidence/mortality in this population. This may explain, at 
least in part, why some populations of footballers [40, 49, 
53, 78], Olympians [39, 46] and baseballers [51] all have 
similar rates of cancer incidence and mortality to the general 
population, whilst others demonstrate a reduced risk [33, 
34, 42, 45].
Endurance athletes’ risk of cancer mortality was not 
significantly different from the general population (SMR 
0.73 (0.50–1.07)). Despite this, END athletes have consist-
ently been found to have favourable longevity compared 
to the general population and, indeed, other athletes [29, 
37, 41, 42, 47, 52]. Thus, it is worth considering whether 
the non-protective effect on cancer mortality derives from 
END training, or simply that athletes are living longer and, 
therefore, have a greater chance of developing cancer. Whilst 
distinguishing these factors may be challenging, it deserves 
consideration given that it could alter the interpretation of 
the results presented and future study directions. Regardless 
of their increased longevity, however, END athletes are still 
at a decreased risk of CVD mortality, suggesting the benefit 
of training is maintained throughout the life-span.
4.5  Limitations
Whilst there are numerous strengths, there are limitations to 
this review that require consideration. Specifically, not all 
the athletes within these studies were elite and of national 
standard, although they were all considered to be highly 
trained. Moreover, inferences are not able to be made about 
the specific training that athletes should undertake as such 
data was rarely reported. As such, conclusions regarding 
the long-term effects of participating in specific types of 
training regimes, such as HIIT, resistance or strength train-
ing, are precluded. Furthermore, the small number of stud-
ies included within the POW athlete sub-group, and female 
athletes potentially limits the generalisability of these 
results. It is also noteworthy that some sports may have been 
mis-classified in previous research (for example, Sarna et al. 
[30] classified boxing as a power sport), which could have 
influenced the meta-analysis results. Finally, no inferences 
can be made as to the relative contribution of lifestyle on 
overall mortality. Thus, it is hard to distinguish whether any 
survival benefit observed is because of training, lifestyle 
choices, or most likely, a combination of both.
5  Conclusions
The main conclusions from this review are: (1) overall, male 
and female athletes’ all-cause mortality is significantly lower 
than the general population; (2) sub-group analyses revealed 
END and team sport athletes, but not POW athletes, had 
a reduced all-cause mortality; (3) POW athletes were at 
a similar risk of CVD mortality compared to the general 
population, and; (4) END athletes cancer mortality was not 
significantly different to the general population. However, 
more research is warranted in female and power athletes, 
with a follow-up of ≥ 30 years, to ascertain the long-term 
benefits/consequences of chronic intensive exercise training 
in these populations.
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